NASDAQ:AVDL - Avadel Pharmaceuticals Stock Price, Forecast & News

Avadel Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVDL."

Avadel Pharmaceuticals announced that its board has initiated a share buyback plan on Wednesday, March 28th 2018, which permits the company to buyback $7,000,000.00 in shares, according to EventVestor. This buyback authorization permits the company to repurchase up to 2.7% of its stock through open market purchases. Stock buyback plans are often an indication that the company's leadership believes its stock is undervalued.

Avadel Pharmaceuticals PLC (NASDAQ:AVDL) released its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.27) by $0.03. The business had revenue of $14.23 million for the quarter. Avadel Pharmaceuticals had a negative net margin of 136.46% and a negative return on equity of 608.01%. View Avadel Pharmaceuticals' Earnings History.

Avadel Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Friday, March 20th 2020. View Earnings Estimates for Avadel Pharmaceuticals.

Avadel Pharmaceuticals issued an update on its FY 2019 Pre-Market earnings guidance on Monday, November, 25th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $$55 million, compared to the consensus revenue estimate of $$50.99 million.

3 brokers have issued 12 month price objectives for Avadel Pharmaceuticals' stock. Their forecasts range from $6.00 to $15.00. On average, they anticipate Avadel Pharmaceuticals' share price to reach $9.00 in the next twelve months. This suggests that the stock has a possible downside of 4.3%. View Analyst Price Targets for Avadel Pharmaceuticals.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avadel Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Avadel Pharmaceuticals.

Media coverage about AVDL stock has been trending very negative on Sunday, InfoTrie reports. The research firm identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Avadel Pharmaceuticals earned a coverage optimism score of -3.0 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for Avadel Pharmaceuticals.

Some companies that are related to Avadel Pharmaceuticals include Enanta Pharmaceuticals (ENTA), Opko Health (OPK), Phathom Pharmaceuticals (PHAT), Portola Pharmaceuticals (PTLA), Karyopharm Therapeutics (KPTI), Kiniksa Pharmaceuticals (KNSA), Dermira (DERM), Myovant Sciences (MYOV), I-Mab (ARQT), Gossamer Bio (GOSS), Achillion Pharmaceuticals (ACHN), Applied Therapeutics (APLT), Radius Health (RDUS), Cytokinetics (CYTK) and Stoke Therapeutics (STOK).

Based on aggregate information from My MarketBeat watchlists, some companies that other Avadel Pharmaceuticals investors own include Intelsat (I), Bank of America (BAC), Fossil Group (FOSL), Chaarat Gold (CGH), Associated British Foods (ABF), AMC Entertainment (AMC), Ciena (CIEN), Apollo Global Management (APO), First Data (FDC) and Cypress Semiconductor (CY).

Avadel Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Brandes Investment Partners LP (9.75%), Broadfin Capital LLC (2.75%), Renaissance Technologies LLC (2.28%), Iridian Asset Management LLC CT (0.83%), Keel Point LLC (0.11%) and Perceptive Advisors LLC (0.02%). Company insiders that own Avadel Pharmaceuticals stock include Eric J Ende, Geoffrey Michael Glass, Greg J Divis, James E Flynn, Michael S Anderson and Sandra L Hatten. View Institutional Ownership Trends for Avadel Pharmaceuticals.

AVDL stock was sold by a variety of institutional investors in the last quarter, including Brandes Investment Partners LP and Broadfin Capital LLC. View Insider Buying and Selling for Avadel Pharmaceuticals.

AVDL stock was acquired by a variety of institutional investors in the last quarter, including Iridian Asset Management LLC CT, Keel Point LLC, Renaissance Technologies LLC, Perceptive Advisors LLC, Perceptive Advisors LLC, Carmichael Hill & Associates Inc., Steward Partners Investment Advisory LLC and UBS Group AG. Company insiders that have bought Avadel Pharmaceuticals stock in the last two years include Eric J Ende, Geoffrey Michael Glass, Greg J Divis and Michael S Anderson. View Insider Buying and Selling for Avadel Pharmaceuticals.

Shares of AVDL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AVDL stock can currently be purchased for approximately $9.40.

Avadel Pharmaceuticals has a market capitalization of $352.03 million and generates $103.27 million in revenue each year. The company earns $-95,300,000.00 in net income (profit) each year or ($1.99) on an earnings per share basis. Avadel Pharmaceuticals employs 144 workers across the globe.View Additional Information About Avadel Pharmaceuticals.

The official website for Avadel Pharmaceuticals is http://www.avadel.com/.

Avadel Pharmaceuticals' mailing address is BLOCK 10-1 BLANCHARDSTOWN CORPORATE PARK BALLYCOOLIN, DUBLIN L2, 63005. The company can be reached via phone at 353-1485-1200 or via email at [email protected]